Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of "Buy" by Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) have received an average rating of "Buy" from the five analysts that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have issued a report on the stock in the last year is $39.60.

Several research firms recently issued reports on ELVN. Jones Trading dropped their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research note on Friday, May 16th. HC Wainwright lifted their price objective on Enliven Therapeutics from $39.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, May 15th. The Goldman Sachs Group began coverage on Enliven Therapeutics in a research note on Monday. They set a "buy" rating and a $37.00 price objective for the company. Finally, Robert W. Baird lifted their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CEO Samuel Kintz sold 5,000 shares of the firm's stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $16.42, for a total transaction of $82,100.00. Following the sale, the chief executive officer now owns 985,392 shares in the company, valued at $16,180,136.64. This trade represents a 0.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Joseph P. Lyssikatos sold 5,030 shares of the firm's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $20.07, for a total value of $100,952.10. Following the sale, the insider now owns 992,658 shares in the company, valued at $19,922,646.06. The trade was a 0.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 88,611 shares of company stock worth $1,695,914 over the last 90 days. Corporate insiders own 25.90% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Rhumbline Advisers increased its holdings in shares of Enliven Therapeutics by 4.9% in the first quarter. Rhumbline Advisers now owns 52,502 shares of the company's stock worth $1,033,000 after buying an additional 2,466 shares during the period. Jane Street Group LLC purchased a new position in shares of Enliven Therapeutics in the first quarter worth about $578,000. Goldman Sachs Group Inc. increased its holdings in shares of Enliven Therapeutics by 61.3% in the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company's stock worth $4,167,000 after buying an additional 80,506 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Enliven Therapeutics by 8.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company's stock worth $428,000 after buying an additional 1,693 shares during the period. Finally, Ally Bridge Group NY LLC increased its holdings in shares of Enliven Therapeutics by 19.8% in the first quarter. Ally Bridge Group NY LLC now owns 169,774 shares of the company's stock worth $3,341,000 after buying an additional 28,064 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Trading Down 1.1%

Shares of ELVN traded down $0.23 on Monday, reaching $21.57. 423,893 shares of the company's stock traded hands, compared to its average volume of 292,627. The stock's 50 day simple moving average is $18.65 and its two-hundred day simple moving average is $20.61. Enliven Therapeutics has a 52-week low of $13.30 and a 52-week high of $30.03. The stock has a market cap of $1.06 billion, a PE ratio of -11.23 and a beta of 0.79.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). Analysts forecast that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.